Adverse drug reactions resulting from COVID-19 treatment in university members
DOI:
https://doi.org/10.47186/visct.v7i1.111Abstract
Objective: To analyze the extent to which members of the community of a private university report the presentation of adverse drug reactions related to COVID-19 pharmacotherapy. Material and Methods: Quantitative approach, cross-sectional descriptive type, non-experimental design, the sample was 159 members of the university community, stratified probabilistic sampling, the technique was a virtual survey, the instrument was a questionnaire made with Google Forms; the results were expressed as mean, standard deviation, percentage frequency, and for the statistical analysis the following tests were used: chi square and 95% confidence interval with a significance level 0.05. Results: most of the participants were female (63.32%), married (59.12%) and with a mean age of 44.46 years; most of them were teachers (50.31%), from the School of Pharmaceutical Sciences and Biochemistry; 44.65% (71 persons) contracted the covid-19 disease; 94.37% (67 persons) were treated at home and only 2.82% had to go to the hospital for treatment. 82%, had to resort to the hospital; currently 100% are vaccinated; 100% took medication, highlighting the use of antibacterials with 27.65%; 49.30% of the people who became ill manifested adverse events, within these stand out colic (34.04%) and stomach discomfort (29.79%), being the gastrointestinal system most affected. Conclusions: Approximately half of the community members of a Private university presented adverse drug reactions related to COVID-19 pharmacotherapy, with colic being the main RAM.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Lizzy Jeanette Mendoza Gutierrez , Diana Esmeralda Andamayo Flores , Mónica Alejandra Calle Vilca , Luis Alejandro Calle Vilca

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Tah Journal Visionarios en Ciencia y Tecnología is distributed under a Creative Commons Attribution 4.0 International License.
Copyright is retained by the authors, who have the right to share, copy, distribute, perform, and publicly communicate their article, or parts of it, provided that the original publication in the journal is acknowledged
Authors may archive in the repository of their institution:
- The thesis from which the published article derives.
- The pre-print version: version prior to peer review.
- The post-print version: final version after peer review.
- The final version or final version created by the editor for publication